EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A Mackintosh iD, Gregory Keir iD, Lauren K Troy, Anne E Holland iD, Christopher Grainge iD, Daniel C Chambers iD, Debra Sandford, Helen E Jo, Ian Glaspole iD, Margaret Wilsher iD, Nicole S L Goh iD, Paul N Reynolds iD and 6 more

Respirology · 2024-02 · 29 (2) · 105-135

DOI: 10.1111/resp.14656 ↗

At a glance

Journal article in Respirology, published online on 2024-01-11. Written by John A Mackintosh and 17 co-authors. Institution: Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia. Major MEDLINE topics: Idiopathic Pulmonary Fibrosis. Cited 52 times so far (Crossref); 291 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHMRC, The Thoracic Society of Australia and New Zealand and Lung Foundation Australia, National Health and Medical Research Council.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.

Subjects

MeSH terms (MEDLINE)

Idiopathic Pulmonary FibrosisHumansNew ZealandFibrosisAustraliaPyridones

Author keywords

idiopathic pulmonary fibrosisinterstitial lung diseaseprogressive pulmonary fibrosispulmonary fibrosistreatment

Substances

Pyridones

Authors and institutions

  • Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
  • Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
  • Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.

ORCID profiles: John A Mackintosh, Gregory Keir, Anne E Holland, Christopher Grainge, Daniel C Chambers, Ian Glaspole, Margaret Wilsher, Nicole S L Goh, Paul N Reynolds, Yuben Moodley, Tamera J Corte

Funding

  • NHMRC
  • The Thoracic Society of Australia and New Zealand and Lung Foundation Australia
  • National Health and Medical Research Council

Cite

APA

Mackintosh, J. A., Keir, G., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., Wilsher, M., Goh, N. S. L., Reynolds, P. N., Chapman, S., Mutsaers, S. E., de Boer, S., Webster, S., Moodley, Y., & Corte, T. J. (2024). Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology, 29(2), 105-135. https://doi.org/10.1111/resp.14656

Vancouver

Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, et al. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. 2024;29(2):105-135. doi:10.1111/resp.14656

BibTeX
@article{Mackintosh2024,
  author = {Mackintosh, John A and Keir, Gregory and Troy, Lauren K and Holland, Anne E and Grainge, Christopher and Chambers, Daniel C and Sandford, Debra and Jo, Helen E and Glaspole, Ian and Wilsher, Margaret and Goh, Nicole S L and Reynolds, Paul N and Chapman, Sally and Mutsaers, Steven E and de Boer, Sally and Webster, Susanne and Moodley, Yuben and Corte, Tamera J},
  title = {Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision},
  journal = {Respirology},
  year = {2024},
  volume = {29},
  number = {2},
  pages = {105--135},
  doi = {10.1111/resp.14656}
}
Start for free →